Safety and Immunogenicity of a <i>Klebsiella pneumoniae</i> Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I/II Randomized and Controlled Study
Kleb4V is the first K. pneumoniae conjugate vaccine candidate to reach clinical assessment. The Kleb4V bioconjugate was immunogenic and well tolerated in the target population of adults aged 55-70 years for the vaccine-serotypes.
Authors
- Patricia Martín (ORCID: https://orcid.org/0009-0007-6223-7942)
- Michael Kowarik (ORCID: https://orcid.org/0000-0002-6512-9855)
- Cristina Alaimo
- Nathalie Karaky
- Steffen Haffner
- Emma Bownes
- David Goldblatt (ORCID: https://orcid.org/0000-0002-0769-5242)
- R Lawrence (ORCID: https://orcid.org/0009-0006-9435-8266)
Institutions
- Great Ormond Street Hospital (GB)
- Spital Limmattal (CH)
- Nuvisan (Germany) (DE)
- Institute of Infection and Immunity (CA)
- University College London (GB)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1093/infdis/jiaf600
- Citations
- 2
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.18